Skip to Content

CSL focused on creating medical breakthroughs

Fri 24 August 2018 09:20 AM Stocks to watch

Recent articles

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.

 

Althea_still

Cannabis stock uses technology for competitive edge

Althea Group CEO Josh Fegan discusses how his company’s technology platform is helping drive growth in medicinal cannabis patient numbers.

18 July 2019 Stocks to watch
Nearmap_still

Nearmap CEO talks growth and Google

Nearmap CEO and Managing Director Rob Newman explains the company’s business model, its growth potential outside Australia and why he doesn’t believe that Google will become a direct competitor.

1 July 2019 Stocks to watch
Zip Co still

Zip eyes international expansion

Zip Co CEO Larry Diamond says he’s considering overseas expansion as consumers embrace alternative payment methods. He also discusses the company’s share price, partner sign-ups and risks.

28 May 2019 Stocks to watch
EMVision

Medical disruptor trials imaging technology

Dr. Ron Weinberger, CEO of the recently listed EMVision Medical Devices, discusses the company’s ambition to bring portable scanning technology directly to patients.

29 March 2019 Stocks to watch